Fundamental Analysis of XOMAP
XOMA Royalty Corporation operates as a biotech royalty aggregator, acquiring milestone and royalty rights on therapeutic candidates licensed to pharmaceutical and biotech partners. The company's model provides non-dilutive, non-recourse funding to sellers, generating recurring income from a diversified portfolio of commercial and development-stage assets. As of the most recent fiscal year (FY2025), XOMA reported revenue of $52.1 million, net income of $31.7 million (60.8% net margin), and diluted EPS of $1.46, reflecting strong profitability on a GAAP basis. However, operating cash flow was only $2.9 million, significantly below net income, due to non-cash items and changes in working capital. The balance sheet shows a current ratio of 3.37 and a manageable debt-to-equity ratio of 1.1, though interest coverage is low (0.375x), indicating some pressure from interest expenses. The recent announcement of Ligand Pharmaceuticals acquiring XOMA Royalty (effective August 2026) is a significant catalyst, offering a premium to shareholders and expanding Ligand's royalty portfolio to over 200 assets. The preferred shares (XOMAP) provide a fixed 8.625% dividend yield, though the acquisition may affect the continuation of these dividends. The company's portfolio includes commercial products like VABYSMO and OJEMDA, plus several investigational assets, providing diversification but also binary clinical risks. Geographically, XOMA operates in the US, Switzerland, Asia Pacific, and Australia. Key strengths include a unique business model, a growing portfolio through acquisitions (e.g., Turnstone, HilleVax, LAVA), and a driven management team. Risks include reliance on partner drug success, regulatory hurdles, and the pending acquisition's execution. The stock trades at a price-to-earnings ratio of ~15x and a dividend yield of 8.6%, offering income potential. Overall, the fundamental outlook is positive, supported by the strategic acquisition, but investors should monitor integration risks and dividend stability.
